A nano-microsphere targeted synergistic drug system and its preparation method and application
By combining MMP9-specific short peptides on graphene oxide quantum dots and encapsulating minocycline to form nanomicrospheres C18PGM, the problem of major side effects of existing drugs for treating choroidal neovascularization is solved, significantly inhibiting MMP9 and inflammatory responses, and improving treatment Effect.
Patent Information
- Application Number
- CN202310192517.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-02
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2043-03-02
AI Technical Summary
The existing drugs for treating choroidal neovascularization have great side effects. Patients have intrinsic or acquired resistance to anti-angiogenesis treatment dominated by VEGF, and long-term use of glucocorticoids may lead to serious side effects such as steroid-induced high intraocular pressure and glaucoma.
Develop a nanomicrosphere-targeted synergistic drug system based on graphene oxide quantum dots. By combining short peptides specifically recognized by MMP9 with graphene oxide quantum dots and encapsulating minocycline, nanomicrospheres C18PGM are used. Its anti-inflammatory and macrophage inhibitory effects interfere with the inflammation-MMP9-angiogenesis cascade.
Significantly inhibit MMP9 activity and inflammatory response, reduce angiogenesis, improve the therapeutic effect on choroidal neovascularization, reduce the side effects of repeated injection of anti-VEGF drugs, and enhance the therapeutic effect.
Smart Images

Figure CN116059174B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to a nano-microsphere targeted synergistic drug system based on graphene oxide quantum dots, and a preparation method and application thereof. Background Art
[0002] Choroidal neovascularization (CNV) is the main clinical manifestation of many vision-threatening fundus diseases, such as age-related macular degeneration, polypoidal choroidal vasculopathy, pathological myopia, and idiopathic choroidal neovascularization. Choroidal neovascularization has high permeability, often leading to subretinal hemorrhage and necrosis of photoreceptor cells due to leakage and deposition, ultimately leading to sudden loss of central vision, and is an important cause of rapid and irreversible vision loss in clinical practice.
[0003] Age-related macular degeneration (AMD), especially wet AMD with choroidal neovascularization (CNV), is a common cause of blindness in middle-aged and elderly patients. Its pathological process is choroidal destruction, chronic inflammation, oxidative stress and overexpression of matrix metalloproteinase 9 (MMP9) causing secondary damage, while the increase in macrophage infiltration further aggravates the inflammatory process and then enhances pathological fundus neovascularization.
[0004] Currently, intraocular injection of anti-VEGF drugs has been widely used in the clinical treatment of choroidal neovascularization. However, there are still many problems to be solved, such as patients' intrinsic or acquired resistance to VEGF-based anti-angiogenic therapy, devastating ocular complications (such as infectious endophthalmitis, increased intraocular pressure, vitreous hemorrhage, and retinal detachment).
[0005] A large number of studies have confirmed that persistent low-grade chronic inflammation (inflammatory response) and the destruction of retinal homeostasis are synergistically involved in the occurrence, development and progression of choroidal neovascularization. Choroidal neovascularization causes structural and functional abnormal blood vessels accompanied by abnormal local blood circulation, leading to ischemia and hypoxia, thereby inducing mitochondrial damage-related oxidative stress to produce a large number of reactive oxygen species (ROS), which can further aggravate inflammation. In addition, in mouse models of laser-induced CNV and human patients, studies have described the massive infiltration of immune cells (such as macrophages and microglia) in Bruch's membrane and subretinal areas. Infiltrating macrophages stimulated by inflammation secrete a variety of angiogenic growth factors (such as VEGF) and abundant inflammatory mediators. At the same time, neovascularization can promote the further infiltration of immune cells into the lesion site, and excessive pro-inflammatory signaling and pathological angiogenesis reinforce each other and perpetuate disease activity. Glucocorticoids are commonly used anti-inflammatory and immunosuppressive drugs in clinical practice, which can block the production of VEGF and inhibit the effects of inflammatory mediators. However, long-term exposure to glucocorticoids can lead to the development of steroid-induced ocular hypertension, which in turn can lead to the development of steroid-induced glaucoma, with the potential for serious side effects.
[0006] In addition, studies have shown that a variety of inflammatory mediators can significantly upregulate matrix metalloproteinase 9 (a zinc-dependent endopeptidase; MMP9), which plays a key role in the proliferation and migration of endothelial cells. In addition, the positive feedback effect between MMP9 and VEGF can cause high expression in lesions. Inhibition of MMP9 activity has been shown to have a significant inhibitory effect on CNV.
[0007] Therefore, the use of a combination strategy to inhibit chronic inflammatory responses and matrix metalloproteinase-9 expression is a way to overcome anti-VEGF treatment resistance and thus solve the current challenges faced by CNV treatment. Summary of the invention
[0008] To this end, the present invention provides a nano-microsphere targeted synergistic drug system and a preparation method and application thereof, so as to solve the problem of large side effects of existing drugs for treating choroidal neovascularization.
[0009] The nano-microsphere targeted synergistic drug system based on graphene oxide quantum dots claimed for protection in the present invention utilizes a short peptide (GVFHQTVSR) (the short peptide is referred to as C18P) that can be specifically recognized and cleaved by MMP9 to be combined with the surface of graphene oxide quantum dots GOQDs, and forms nano-microspheres C18PGM by encapsulating minocycline MC.
[0010] Graphene oxide quantum dots (GOQDs) as natural antioxidants can play an anti-inflammatory role, while minocycline (MC) is a specific macrophage inhibitor that can inhibit the activation of macrophages and the expression of MMP9. Here, the present invention develops a nano-microsphere targeted synergistic drug system (C18PGM) by chemically bonding GOQDs with a short peptide (C18-GVFHQTVS, C18P) that can be sensitive to MMP9. Using an in vitro inflammatory cell model treated with lipopolysaccharide (LPS) and a laser-induced CNV mouse model, the prepared C18PGM showed significant MMP9 inhibitory activity and anti-inflammatory effects, thereby exerting an anti-angiogenic effect. In addition, C18PGM is used in combination with bevacizumab to synergistically increase the anti-angiogenic effect in vivo by interfering with the "inflammation-MMP9-angiogenesis" cascade reaction. The results show that the C18PGM prepared by the present invention is an effective and novel strategy for treating CNV.
[0011] In order to achieve the above object, the present invention provides the following technical solutions:
[0012] According to the first aspect of the present invention, a nano-microsphere targeted synergistic drug system is provided, wherein the drug system is prepared by modifying graphene oxide quantum dots with short peptides sensitive to matrix metalloproteinase MMP9 and encapsulating minocycline.
[0013] Furthermore, the short peptide is a short peptide C18P that is sensitive to matrix metalloproteinase MMP9.
[0014] Furthermore, the short peptide contains a hydrophobic N-terminal region, which can be specifically recognized and cut by MMP9; the short peptide is modified with a straight-chain octadecyl group, which can functionally expand the hydrophobic end of the MMP9-responsive short peptide.
[0015] The present invention constructs a short peptide (C18P) that can be specifically recognized and cleaved by MMP9, which consists of two parts: a short peptide (GVFHQTVSR) containing a hydrophobic N-terminal region, wherein the short peptide can be specifically recognized and cleaved by MMP9; secondly, the short peptide is modified by a straight-chain octadecyl (18-carbon) (C18), which can functionally expand the hydrophobic end of the MMP9-responsive short peptide.
[0016] According to the second aspect of the present invention, a method for preparing a nano-microsphere targeted synergistic drug system is provided, comprising:
[0017] Step 1, Preparation of C18PG
[0018] The amphiphilic polymer C18PG was formed by chemically bonding C18P with graphene oxide quantum dots GOQDs;
[0019] Step 2: Preparation of C18PGM
[0020] The hydrophilic minocycline MC was encapsulated in the amphiphilic polymer C18PG to prepare C18PGM using the emulsion method.
[0021] Furthermore, the step one is specifically as follows: dissolving GOQDs in MES buffer and EDC to activate the carboxyl groups; then adding NHS and C18P and stirring vigorously overnight to fully carry out the condensation reaction; and preparing C18PG.
[0022] Furthermore, the step 2 is specifically as follows: dissolving C18PG in a minocycline aqueous solution, and then adding the obtained solution dropwise into a n-hexane solution; the obtained product is evaporated overnight in vacuum to obtain a precipitate, namely C18PGM.
[0023] According to the third aspect of the present invention, a nano-microsphere targeted synergistic drug system is provided for use in preparing a product for treating choroidal neovascularization diseases.
[0024] The drug system of the present invention can also be used in the preparation of products for resisting fundus neovascularization.
[0025] The drug system (C18PGM system) is a microsphere with an average particle size of about 2 μm. Dynamic light scattering data showed that the water-dispersed particle size of C18PGM was about 3113.33±371.87 nm and the Zeta potential was about -9.18±1.35 mV. The successful synthesis of the drug system was confirmed by energy dispersive X-ray (EDX) analysis.
[0026] Furthermore, the choroidal neovascularization disease is age-related maculopathy, pathological myopia, ocular trauma, uveitis or idiopathic choroidal neovascularization.
[0027] In summary, the pharmaceutical system of the present invention is used in any of the following:
[0028] (1) preparing a product for treating and / or preventing disease A;
[0029] (2) preparing a product for alleviating the symptoms of said disease A;
[0030] The disease A meets the following conditions: 1) anti-VEGF drugs can be used for treatment and / or prevention, or the use of anti-VEGF drugs can alleviate symptoms; 2) inflammatory cell infiltration exists in the lesion site, and MMP9 is highly expressed.
[0031] According to the fourth aspect of the present invention, a nano-microsphere targeted synergistic drug system is provided for use in the preparation of a drug transport carrier including minocycline.
[0032] The present invention has the following advantages:
[0033] The drug system provided by the present invention is based on the anti-ROS and carrier properties of graphene oxide quantum dots. The short peptide C18P that can be targeted and cut by MMP9 is used to modify graphene oxide quantum dots, and minocycline is encapsulated inside to construct a C18PGM system that can respond to MMP9 at the lesion site. The system delivers minocycline to the fundus lesion site through intravitreal injection, releases minocycline and graphene quantum dots in response to MMP9 in the lesion, reduces the expression of MMP9 and inflammatory factors, and thus efficiently inhibits CNV by inhibiting "inflammation-MMP9-angiogenesis". It solves the problem of repeated injection of anti-VEGF drugs in current clinical applications, and significantly improves the effect of inhibiting CNV. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] In order to more clearly illustrate the implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the implementation methods or the description of the prior art. Obviously, the drawings in the following description are only exemplary, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.
[0035] The structures, proportions, sizes, etc. illustrated in this specification are only used to match the contents disclosed in the specification so as to facilitate understanding and reading by persons familiar with the technology. They are not used to limit the conditions under which the present invention can be implemented, and therefore have no substantial technical significance. Any structural modification, change in proportion or adjustment of size shall still fall within the scope of the technical contents disclosed in the present invention without affecting the effects and purposes that can be achieved by the present invention.
[0036] Figure 1 Schematic diagram of the construction scheme of nano-microsphere targeted synergistic drug system based on graphene oxide quantum dots.
[0037] Figure 2 This is the transmission electron microscope (TEM) image of C18PG in Example 1.
[0038] Figure 3 This is the transmission electron microscope (TEM) image of C18PGM in Example 1.
[0039] Figure 4 This is a statistical diagram of the particle size and potential of C18PGM measured by the Malvern laser particle size analyzer in Example 1.
[0040] Figure 5 This is a graph showing the cytokine content in the supernatant of the co-culture system of the drug system and RAW 264.7 detected by the Elisa method in Example 2.
[0041] Figure 6The protein immunoblotting experiment in Example 2 analyzed the expression of MMP9 protein in the drug system and RAW 264.7 co-culture system; wherein A is the WB result of MMP9 protein in RAW 264.7 cells; and B is the statistical analysis chart of the WB results.
[0042] Figure 7 These are images of the migration amount and tube-forming ability of HRMECs observed under an optical microscope in Example 2; wherein, A-migration graph of HRMECs; B-statistical analysis graph of migration amount; C-VEGF protein content in the supernatant detected by ELISA; D-migration graph of HRMECs; E-statistical analysis graph of migration amount; F-tube-forming graph of HRMECs; G-statistical analysis graph of tube-forming.
[0043] Figure 8 The laser scanning confocal microscope shows the area and quantitative graph of the neovascularization of the CNV mouse model and the HE staining shows the invasiveness and quantitative graph of the neovascularization of the CNV mouse in Example 3; wherein, A-FA imaging of the choroid of CNV mice and IB4 vascular staining; B-leakage assessment graph of neovascularization of mice; C-HE staining graph of eye tissue of CNV mice; D-invasiveness (length) of neovascularization of CNV mice; E-invasiveness (height) of neovascularization of CNV mice; F-quantitative graph of the average neovascularization area of CNV mice. DETAILED DESCRIPTION
[0044] The following is a description of the implementation of the present invention by specific embodiments. People familiar with the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0045] The abbreviations involved in the present invention are:
[0046] MMP9 - matrix metalloproteinase 9
[0047] MC--minocycline
[0048] GOQDs--Graphene Oxide Quantum Dots
[0049] C18P--short peptide
[0050] C18PG--amphiphilic polymer
[0051] C18PGM--Nano-microsphere targeted synergistic drug system
[0052] MES--morpholineethanesulfonic acid
[0053] EDC--1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
[0054] NHS--N-hydroxysulfosuccinimide
[0055] HRTEM - High Resolution Transmission Electron Microscopy
[0056] Example 1
[0057] This embodiment provides a nano-microsphere targeted synergistic drug system based on graphene oxide quantum dots:
[0058] Figure 1 Schematic diagram of the construction scheme of the nano-microsphere targeted synergistic drug system based on graphene oxide quantum dots: the short peptide C18P sensitive to MMP9 is chemically bonded to the graphene oxide surface (C18PG), and then minocycline is encapsulated in it by the emulsion method to complete the construction of C18PGM. The morphology is observed by transmission electron microscopy (TEM), and the particle size and potential of the system are measured by Malvern laser particle size analyzer.
[0059] Specifically: (1) The C18P short peptide was synthesized by Hubei Qiangyao Biotechnology Co., Ltd. The short peptide consists of two parts: a short peptide containing a hydrophobic N-terminal region (GVFHQTVSR), which can be specifically recognized and cleaved by MMP9; and a short peptide modified with a straight-chain octadecyl (18-carbon) (C18) group, which can functionally expand the hydrophobic end of the MMP9-responsive short peptide.
[0060] (2) GOQDs were dissolved in 5 mL 50 mM MES buffer (pH ≈ 5.5) and 19.7 mg EDC, and the carboxyl groups were activated at 4 °C for 1 h. Subsequently, 22.7 mg NHS and 1 mg C18P were added to the above solution, and then vigorously stirred overnight at 4 °C using an Eppendorf Thermomixer C device (Germany) to fully carry out the condensation reaction. C18PG samples were prepared by mixing GOQD and C18P in MES buffer at mass ratios of 1:1, 1:2, and 1:5, respectively. Finally, the obtained product was purified by dialysis (3000 Da) and the purified product was vacuum dried.
[0061] (3) The C18PGM sample was obtained by the W / O / W emulsion method: C18PG (C18P:GOQDs with a mass ratio of 1:2) was dissolved in 100 μL of minocycline aqueous solution, and then the obtained solution was added dropwise to 5 mL of n-hexane solution; the obtained product was evaporated overnight in vacuum to obtain a precipitate, which was the C18PGM sample.
[0062] The morphology of C18P and C18PGM (e.g. Figure 2 , Figure 3 The average particle size and zeta potential of GOQDs, C18PG and C18PGM were measured using a Malvern Zetasizer (Westborough, MA, USA). Figure 4 shown).
[0063] Conclusion: Figure 2-Figure 4 It can be seen that in Example 1 of the present invention, C18P was successfully bound to the surface of GOQDs, and negatively charged C18PGM microspheres with uniform size of about 2 μm were successfully prepared by the emulsion method.
[0064] Example 2
[0065] This example provides an in vitro anti-inflammatory effect test of the C18PGM prepared in the example:
[0066] The drug system was validated for its in vitro efficacy using macrophages (RAW 264.7) and human retinal microvascular endothelial cells (HRMECs).
[0067] (1) RAW 264.7 cells were co-cultured with GOQDs, C18PG, and C18PGM (40 μg / mL) for 24 h. The cells were treated with or without LPS (500 ng / mL) for 10 h. The expression of cytokines (IL-1β, IL-6, and TNF-α) in the supernatant was detected by ELISA, and the expression of MMP9 protein was detected by western blotting.
[0068] The results show: Figure 5 It can be seen that after C18PGM treatment, the cytokine content in the supernatant was the lowest; Figure 6 It can be seen that after C18PGM treatment, the expression of MMP9 protein was also the lowest.
[0069] (2) After HRMECs were co-incubated with GOQDs, MC, C18PG and C18PGM for 24 h, the migration and angiogenesis ability of HRMECs were evaluated by scratch test, Transwell test and tube formation test, and observed under optical microscopy.
[0070] The results show: Figure 7 It can be seen that the migration ability and angiogenesis ability of the C18PGM-treated group were the lowest.
[0071] These results suggest that C18PGM has anti-inflammatory and anti-MMP9 effects on RAW 264.7 macrophages, and can inhibit the migration, emigration, and angiogenesis of HRMECs.
[0072] Example 3
[0073] This example provides in vivo efficacy verification of C18PGM prepared in Example 1:
[0074] The laser-induced CNV model of C57BL / 6J mice was used to verify the in vivo efficacy of the drug system.
[0075] (1) Construction of laser-induced CNV mouse model. C57BL / 6J mice were anesthetized with 1.25% avertin (20 mg / kg) by intraperitoneal injection, and the pupils were dilated with 1% compound tropicamide eye drops. Laser photocoagulation (spot size of about 50 μm, laser energy of 100 mW, duration of 70 ms) was used to generate 4 to 5 spots at a distance of about 2 to 3 optic disc diameters from the optic nerve. The generation of bubbles indicated the rupture of Bruch's membrane, suggesting that the CNV mouse model was successfully constructed.
[0076] (2) Seven days after modeling, drugs were administered by intravitreal injection. After the CNV model mice were anesthetized, PBS, GOQDs, C18PG and C18PGM were injected into the vitreous cavity using a Hamilton microsyringe (except PBS, the content of each group was 1.5 μg / eye).
[0077] (3) Seven days after administration, the efficacy was observed by HE staining of choroidal flat mounts and retinal sections. After the mouse eyeballs were removed, they were fixed in eyeball fixative for 1 hour. The anterior segment of the eye was removed under a stereomicroscope, and the RPE layer-choroid-sclera complex was made into a petal-like structure and spread on a glass slide. The area of new blood vessels was observed and quantitatively analyzed using a laser scanning confocal microscope. After the eyeballs were removed and fixed, they were embedded in paraffin and made into sections of 3 to 4 μm / slice. After HE staining, they were observed under an optical microscope, and the area of new blood vessels was quantitatively analyzed.
[0078] Laser scanning confocal microscopy shows the area of new blood vessels in the CNV mouse model as shown in the figure. HE staining shows the area of new blood vessel invasion in the CNV mouse model as shown in the figure. Figure 8 shown.
[0079] Depend on Figure 8 It can be seen that C18PGM can effectively inhibit the formation of CNV and enhance the anti-VEGF effect of Bevacizumab.
[0080] The drug system provided by the present invention is based on the anti-ROS and carrier properties of graphene oxide quantum dots. The graphene oxide quantum dots are modified with a short peptide C18P that can be targeted and cleaved by MMP9, minocycline is encapsulated therein, and a C18PGM system that can respond to MMP9 in the lesion site is constructed.
[0081] This system delivers minocycline to the fundus lesions through intravitreal injection, releases minocycline and graphene quantum dots in response to MMP9 in the lesions, reduces the expression of MMP9 and inflammatory factors, and effectively inhibits CNV by inhibiting "inflammation-MMP9-angiogenesis". It solves the problem of repeated injection of anti-VEGF drugs in current clinical applications and significantly improves the effect of inhibiting CNV.
[0082] Although the present invention has been described in detail above by general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.
Claims
1. A nano-microsphere targeted synergistic drug system, It is characterized in that The drug system is prepared by modifying graphene oxide quantum dots with short peptides sensitive to matrix metalloproteinase MMP9 and encapsulating minocycline; The short peptide is a short peptide C18P that is sensitive to matrix metalloproteinase MMP9; The short peptide contains a hydrophobic N-terminal region and can be specifically recognized and cleaved by MMP9; The short peptide is modified with a straight-chain octadecyl group, which can functionally extend the hydrophobic end of the MMP9-responsive short peptide; The preparation method of the nano-microsphere targeted synergistic drug system comprises: Step 1, Preparation of C18PG The amphiphilic polymer C18PG was formed by chemically bonding C18P with graphene oxide quantum dots GOQDs; Step 2: Preparation of C18PGM The hydrophilic minocycline MC was encapsulated in the amphiphilic polymer C18PG to prepare C18PGM using the emulsion method.
2. A nano-microsphere targeted synergistic drug system according to claim 1, It is characterized in that The step 1 is specifically as follows: dissolving GOQDs in MES buffer and EDC to activate the carboxyl groups; then adding NHS and C18P and stirring vigorously overnight to fully carry out the condensation reaction; and preparing C18PG.
3. A nano-microsphere targeted synergistic drug system according to claim 1, It is characterized in that The step 2 is specifically as follows: dissolving C18PG in a minocycline aqueous solution, and then dropping the obtained solution into a n-hexane solution; the obtained product is evaporated overnight in vacuum to obtain a precipitate, namely C18PGM.
4. Use of the nano-microsphere targeted synergistic drug system according to claim 1 in the preparation of products for treating choroidal neovascularization diseases.
5. The use according to claim 4, It is characterized in that The choroidal neovascularization disease is age-related macular degeneration, pathological myopia, ocular trauma, uveitis or idiopathic choroidal neovascularization.
6. Use of the nano-microsphere targeted synergistic drug system according to claim 1 in the preparation of a drug transport carrier including minocycline.
